title: Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
abstract: The term nonalcoholic steatohepatitis (NASH) has recently been proposed to identify a fatty liver disease accompanied by diffuse fatty infiltration and inflammation. However, no drug therapy has been established for NASH as yet. In the present study, we demonstrate the effect of the angiotensin II type 1 receptor antagonist telmisartan on the development of NASH in a rat model. Telmisartan, but not the angiotensin receptor antagonist valsartan, markedly attenuated hepatic steatosis, inflammation, and fibrosis in these rats. The quantitative parameters of steatosis, inflammation, and fibrosis were also ameliorated by treatment with telmisartan. Compared with telmisartan, the peroxisome proliferator-activated receptor-gamma agonist pioglitazone attenuated hepatic steatosis and fibrosis of the liver to a similar degree. However, telmisartan, but not pioglitazone, dramatically decreased both subcutaneous and visceral fat. In conclusion, these results indicated that telmisartan should be the drug of first choice for the treatment of patients with NASH.
authors.affiliation: Division of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Fujita
authors.forename: Masato
authors.initials: M
authors.lastname: Yoneda
authors.forename: Koichiro
authors.initials: K
authors.lastname: Wada
authors.forename: Hironori
authors.initials: H
authors.lastname: Mawatari
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kirikoshi
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Nozaki
authors.forename: Shiro
authors.initials: S
authors.lastname: Maeyama
authors.forename: Satoru
authors.initials: S
authors.lastname: Saito
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
mesh_terms: D000199:Actins / Q000096:biosynthesis; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D015153:Blotting, Western; D024042:Collagen Type I / Q000096:biosynthesis; D004195:Disease Models, Animal; D018450:Disease Progression; D005234:Fatty Liver / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007150:Immunohistochemistry; D008297:Male; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism; D000077205:Pioglitazone; D051381:Rats; D011916:Rats, Inbred F344; D013053:Spectrophotometry; D000077333:Telmisartan; D013777:Tetrazoles / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000199:Actins; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D015415:Biomarkers; D024042:Collagen Type I; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D013777:Tetrazoles; D045162:Thiazolidinediones; D000068756:Valsartan; D014633:Valine; D000077333:Telmisartan; D000077205:Pioglitazone